Availability of drugs for severe COVID-19 in sub-Saharan Africa

Sylvain Raoul Simeni Njonnou; Christian Ngongang Ouankou; Fernando Kemta Lekpa; Eric Vounsia Balti; Simeon Pierre Choukem

doi:10.11604/pamj.supp.2020.35.2.23698

Availability of drugs for severe COVID-19 in sub-Saharan Africa

Pan Afr Med J. 2020 May 26;35(Suppl 2):48. doi: 10.11604/pamj.supp.2020.35.2.23698. eCollection 2020.

Authors

Sylvain Raoul Simeni Njonnou^{1

2}, Christian Ngongang Ouankou^{1

2

3}, Fernando Kemta Lekpa^{1

2

4}, Eric Vounsia Balti^{1

2

5}, Simeon Pierre Choukem^{1

2

6}

Affiliations

¹ Department of Internal Medicine and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.
² The University of Dschang Taskforce for the Elimination of COVID-19 (UNITED#COVID-19*), Dschang, Cameroon.
³ Department of Internal Medicine and Specialties, Yaoundé University Teaching Hospital, Yaoundé, Cameroon.
⁴ Department of Internal Medicine, Douala General Hospital, Douala, Cameroon.
⁵ Diabetes Research Center and Department of Internal Medicine, Universiteit Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
⁶ Health and Human Development (2HD) Research Network, Douala, Cameroon.

No abstract available

Keywords: COVID-19; drug availability; effective treatment; severe.

Publication types

Letter

MeSH terms

Africa South of the Sahara
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / pharmacology
COVID-19 / physiopathology
COVID-19 Drug Treatment*
Humans
Receptors, Interleukin-6 / immunology*
Severity of Illness Index

Substances

Antibodies, Monoclonal, Humanized
Receptors, Interleukin-6
tocilizumab